Last updated on May 2019

A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease.


Brief description of study

The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with mild cognitive impairment due to Alzheimer's Disease (MCI due to AD) also known as prodromal AD.

 

Clinical Study Identifier: TX219746

Find a site near you

Start Over

NeuroStudies

2665 N. Decatur Rd. Suite 740 Decatur, GA United States
  Connect »